, a bio/informatics shared resource is still "open for business" - Visit the CDS website

Thomas Golper
Last active: 4/25/2016

L-carnitine treatment of anemia.

Golper TA, Goral S, Becker BN, Langman CB
Am J Kidney Dis. 2003 41 (4 Suppl 4): S27-34

PMID: 12751051 · DOI:10.1016/s0272-6386(03)00114-8

Recombinant human erythropoietin (rHuEPO) and iron supplementation have had a profoundly positive impact on the anemia of patients with chronic kidney disease. However, a significant number of patients remain hyporesponsive to rHuEPO, with hemoglobin values less than target levels. A suboptimal response to rHuEPO is associated with complications that can reduce quality of life and increase morbidity, mortality, and costs. There are a number of other metabolic derangements associated with uremia that can impact on the production and survival of red blood cells. Dialysis-related carnitine disorder is a functional metabolic deficiency, common in chronic dialysis patients, that can have a negative impact on erythrocyte production and survival. This article reviews the role of L-carnitine in the pathogenesis and adjunctive treatment of anemia associated with kidney failure. After a comprehensive database search, primary and secondary reports were analyzed. Laboratory studies examining the influence of carnitine on red blood cell function and clinical trials of L-carnitine in dialysis patients support the use of L-carnitine in the setting of rHuEPO hyporesponsiveness. Consensus groups, including the National Kidney Foundation-Kidney Disease Outcome Quality Initiative (K/DOQI), consider the use of L-carnitine for hyporesponsive rHuEPO-dependent anemia a promising application of this therapy, recommending an empiric trial of L-carnitine in these patients.

MeSH Terms (6)

Anemia Carnitine Erythrocytes Humans Kidney Failure, Chronic Renal Dialysis

Connections (1)

This publication is referenced by other Labnodes entities: